Literature DB >> 32242472

Natural and vaccine-induced B cell-derived systemic and mucosal humoral immunity to human papillomavirus.

Ralph-Sydney Mboumba Bouassa1,2,3, Hélène Péré1,3,4, Mohammad-Ali Jenabian5, David Veyer1, Jean-François Meye6, Antoine Touzé7, Laurent Bélec1,3,4.   

Abstract

Introduction: Human papillomavirus (HPV) are the causative agent of mucosal neoplasia. Both cervical, anal and oropharyngeal cancers incidence is constantly increasing, making the HPV infection, a significant worldwide concern. Together, the CD8+ T cytotoxic cell-mediated response and the HPV-specific antibody response control most of the HPV infections before the development of cancers.Areas covered: We searched the MEDLINE and EMBASE databases and identified 228 eligible studies from 1987 to 2019 which examines both naturally acquired and vaccine induced humoral immunity against HPV infection in female and male subjects from worldwide origin. Herein, we synthesize current knowledge on the features of systemic and mucosal humoral immunity against HPV. We discuss the issues of the balance between the viral clearance or the escape to the host immune response, the differences between natural and vaccine-induced HPV-specific antibodies and their neutralizing capability. We also discuss the protection afforded after natural infection or following prophylactic vaccination.Expert opinion: Understanding the antibody response induced by HPV infection has led to the design of first-generation prophylactic vaccines. Now, prophylactic vaccination induces protective and long-lasting antibody response which would also strengthened the natural moderate humoral response in people previously exposed to the virus.

Entities:  

Keywords:  HPV-associated cancers; Human papillomavirus infection; Natural and vaccine-induced humoral immune responses; Neutralizing antibody; Virus-like particle HPV prophylactic vaccine

Mesh:

Substances:

Year:  2020        PMID: 32242472     DOI: 10.1080/14787210.2020.1750950

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  4 in total

1.  Molecular characterization and pathological identification of a novel strain of delta papillomavirus-4 (bovine papillomavirus-2) in Egypt.

Authors:  Rabab T Hassanien; Mervat E Hamdy; Sara M Elnomrosy; Heba A Hussein; Ahmed F Afify; Fatma M Darwish; Gehan Shehab; Rawhya Emran; Mervat I I Abd-El-Moniem; Ahmed R Habashi; Hanan A Fahmy; Essam M Ibraheem; Momtaz A Shahein; Mohamed Attya; Ali M M Abdelhakim; Naglaa M Hagag
Journal:  Vet World       Date:  2021-09-03

2.  Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway.

Authors:  Meiying Li; Jianmei Huang; Guonan Zhang; Jianming Huang; Yi Zhu; Ziyi Huang
Journal:  Virol J       Date:  2022-05-26       Impact factor: 5.913

Review 3.  Genetic instability and anti-HPV immune response as drivers of infertility associated with HPV infection.

Authors:  Maria Isaguliants; Stepan Krasnyak; Olga Smirnova; Vincenza Colonna; Oleg Apolikhin; Franco M Buonaguro
Journal:  Infect Agent Cancer       Date:  2021-05-10       Impact factor: 2.965

4.  In vitro inhibitory activity against HPV of the monoterpenoid zinc tetra-ascorbo-camphorate.

Authors:  Ralph Sydney Mboumba Bouassa; Bernard Gombert; Gabin Mwande-Maguene; Aurèle Mannarini; Laurent Bélec
Journal:  Heliyon       Date:  2021-06-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.